Firefly Neuroscience
About Firefly Neuroscience
Firefly Neuroscience operates as a medical technology company focused on brain health diagnostics through its FDA-cleared Brain Network Analytics (BNA™) platform. The system analyzes electroencephalography (EEG) data using a proprietary database containing over 17,000 standardized recordings.
BNA™ technology processes Event-Related Potentials (ERPs), spectral EEG patterns and behavioral performance metrics to generate objective assessments of brain function. Healthcare providers use these evaluations to support clinical decisions related to traumatic brain injuries, Alzheimer's disease, Parkinson's disease and other neurological conditions.
The platform applies automated analysis methods to convert raw EEG signals into standardized reports that measure cognitive performance, attention, memory and executive function. This approach provides clinicians with quantifiable data points rather than relying solely on subjective symptom reporting.
Firefly Neuroscience serves hospitals, research institutions and specialty neurology practices seeking data-driven tools for brain health assessment. The company continues to expand its reference database and refine its analytical algorithms to improve diagnostic precision across diverse patient populations.
Firefly Neuroscience Is Acquiring Proprietary Brain Mapping Data
Firefly Neuroscience (NASDAQ: AIFF) has acquired Evoke Neuroscience for $6 million for their proprietary cognitive detection technology.
Hemostemix and Firefly Neuroscience Launch New Vascular Dementia Collaboration
Hemostemix and Firefly Neuroscience (NASDAQ: AIFF) have launched a new collaboration to leverage Firefly Neuroscience’s Brain Network Analytics technology.
Firefly Neuroscience Is Funded To Build Foundational AI Brain Models
Firefly Neuroscience (NASDAQ: AIFF) has successfully raised $8.8 million through warrant conversions for their foundational AI brain models.
Firefly Neuroscience Wins Acceptance Into Nvidia Connect Program
Firefly Neuroscience (NASDAQ: AIFF) has officially been accepted into Nvidia’s (NASDAQ: NVDA) Connect Program.
Firefly Neuroscience Is Making AI Powered Breakthroughs In Brain Health
Firefly Neuroscience (NASDAQ: AIFF) has announced they have successfully completed the first ever use of cognitive ERP data for brain age assessment.
Firefly Neuroscience and Bright Minds Biosciences Collaborate On Clinical Trial Data
Firefly Neuroscience (NASDAQ: AIFF) and Bright Mind Biosciences (NASDAQ: DRUG) are collaborating to leverage AI technology for clinical trial data evaluation.
Similar to Firefly Neuroscience
More Companies →Why Firefly Neuroscience Matters
Firefly Neuroscience sits at the intersection of AI-driven diagnostics and neurology, where machine learning algorithms process complex neurophysiological data to identify patterns associated with brain dysfunction. The company's focus on objective biomarkers aligns with broader trends in precision medicine, where quantifiable measurements replace subjective clinical assessments. As healthcare systems prioritize early detection and personalized treatment protocols, technologies that translate biological signals into actionable insights gain clinical and commercial traction.
